189 related articles for article (PubMed ID: 26596710)
1. Discovery of novel quinoline-based mTOR inhibitors via introducing intra-molecular hydrogen bonding scaffold (iMHBS): The design, synthesis and biological evaluation.
Ma X; Lv X; Qiu N; Yang B; He Q; Hu Y
Bioorg Med Chem; 2015 Dec; 23(24):7585-96. PubMed ID: 26596710
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of novel 4-alkynyl-quinoline derivatives as PI3K/mTOR dual inhibitors.
Lv X; Ying H; Ma X; Qiu N; Wu P; Yang B; Hu Y
Eur J Med Chem; 2015 Jun; 99():36-50. PubMed ID: 26046312
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents.
Peng W; Tu ZC; Long ZJ; Liu Q; Lu G
Eur J Med Chem; 2016 Jan; 108():644-654. PubMed ID: 26731167
[TBL] [Abstract][Full Text] [Related]
4. Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors.
Liu KK; Huang X; Bagrodia S; Chen JH; Greasley S; Cheng H; Sun S; Knighton D; Rodgers C; Rafidi K; Zou A; Xiao J; Yan S
Bioorg Med Chem Lett; 2011 Feb; 21(4):1270-4. PubMed ID: 21269826
[TBL] [Abstract][Full Text] [Related]
5. Structural optimization towards promising β-methyl-4-acrylamido quinoline derivatives as PI3K/mTOR dual inhibitors for anti-cancer therapy: The in vitro and in vivo biological evaluation.
He R; Xu B; Ping L; Lv X
Eur J Med Chem; 2021 Mar; 214():113249. PubMed ID: 33561608
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and anticancer effects evaluation of 1-alkyl-3-(6-(2-methoxy-3-sulfonylaminopyridin-5-yl)benzo[d]thiazol-2-yl)urea as anticancer agents with low toxicity.
Xie XX; Li H; Wang J; Mao S; Xin MH; Lu SM; Mei QB; Zhang SQ
Bioorg Med Chem; 2015 Oct; 23(19):6477-85. PubMed ID: 26321603
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of thieno[3,2-d]pyrimidine derivatives containing aroyl hydrazone or aryl hydrazide moieties for PI3K and mTOR dual inhibition.
Han Y; Tian Y; Wang R; Fu S; Jiang J; Dong J; Qin M; Hou Y; Zhao Y
Bioorg Chem; 2020 Nov; 104():104197. PubMed ID: 32927132
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
Zhai X; Bao G; Wang L; Cheng M; Zhao M; Zhao S; Zhou H; Gong P
Bioorg Med Chem; 2016 Mar; 24(6):1331-45. PubMed ID: 26897090
[TBL] [Abstract][Full Text] [Related]
9. Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors.
Mortensen DS; Perrin-Ninkovic SM; Harris R; Lee BG; Shevlin G; Hickman M; Khambatta G; Bisonette RR; Fultz KE; Sankar S
Bioorg Med Chem Lett; 2011 Nov; 21(22):6793-9. PubMed ID: 21978683
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold.
Wurz RP; Liu L; Yang K; Nishimura N; Bo Y; Pettus LH; Caenepeel S; Freeman DJ; McCarter JD; Mullady EL; Miguel TS; Wang L; Zhang N; Andrews KL; Whittington DA; Jiang J; Subramanian R; Hughes PE; Norman MH
Bioorg Med Chem Lett; 2012 Sep; 22(17):5714-20. PubMed ID: 22832322
[TBL] [Abstract][Full Text] [Related]
11. New quinoline/chalcone hybrids as anti-cancer agents: Design, synthesis, and evaluations of cytotoxicity and PI3K inhibitory activity.
Abbas SH; Abd El-Hafeez AA; Shoman ME; Montano MM; Hassan HA
Bioorg Chem; 2019 Feb; 82():360-377. PubMed ID: 30428415
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a series of N-(5-(quinolin-6-yl)pyridin-3-yl)benzenesulfonamides as PI3K/mTOR dual inhibitors.
Zhang J; Lv X; Ma X; Hu Y
Eur J Med Chem; 2017 Feb; 127():509-520. PubMed ID: 28109945
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR.
Chen SM; Liu JL; Wang X; Liang C; Ding J; Meng LH
Biochem Pharmacol; 2012 May; 83(9):1183-94. PubMed ID: 22305748
[TBL] [Abstract][Full Text] [Related]
14. 4-(N-Phenyl-N'-substituted benzenesulfonyl)-6-(4-hydroxyphenyl)quinolines as inhibitors of mammalian target of rapamycin.
Venkateswarlu V; Pathania AS; Aravinda Kumar KA; Mahajan P; Nargotra A; Vishwakarma RA; Malik FA; Sawant SD
Bioorg Med Chem; 2015 Aug; 23(15):4237-4247. PubMed ID: 26162498
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis, and Biological Evaluation of Imidazo[1,2-
Yu Y; Han Y; Zhang F; Gao Z; Zhu T; Dong S; Ma M
J Med Chem; 2020 Mar; 63(6):3028-3046. PubMed ID: 32069401
[TBL] [Abstract][Full Text] [Related]
16. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and antitumor activity evaluation of PI3K inhibitors containing 3-substituted quinazolin-4(3H)-one moiety.
Zhang H; Xin MH; Xie XX; Mao S; Zuo SJ; Lu SM; Zhang SQ
Bioorg Med Chem; 2015 Dec; 23(24):7765-76. PubMed ID: 26652969
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, in-vitro antiproliferative activity and kinase profile of new picolinamide based 2-amido and ureido quinoline derivatives.
El-Damasy AK; Seo SH; Cho NC; Kang SB; Pae AN; Kim KS; Keum G
Eur J Med Chem; 2015 Aug; 101():754-68. PubMed ID: 26218653
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and antiproliferative activity evaluation of m-(4-morpholinyl-1,3,5-triazin-2-yl)benzamides in vitro.
Wang XM; Xu J; Xin MH; Lu SM; Zhang SQ
Bioorg Med Chem Lett; 2015 Apr; 25(8):1730-1735. PubMed ID: 25765909
[TBL] [Abstract][Full Text] [Related]
20. Design and development of Tetrahydro-Quinoline derivatives as dual mTOR-C1/C2 inhibitors for the treatment of lung cancer.
Chaube UJ; Rawal R; Jha AB; Variya B; Bhatt HG
Bioorg Chem; 2021 Jan; 106():104501. PubMed ID: 33280832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
